Zoetis Inc. (NYSE:ZTS) – Research analysts at Jefferies Group decreased their FY2018 earnings per share (EPS) estimates for shares of Zoetis in a note issued to investors on Thursday. Jefferies Group analyst J. Holford now anticipates that the brokerage will earn $2.78 per share for the year, down from their previous forecast of $2.79. Jefferies Group has a “Buy” rating and a $63.00 price objective on the stock. Jefferies Group also issued estimates for Zoetis’ FY2019 earnings at $3.18 EPS and FY2020 earnings at $3.59 EPS.
Zoetis (NYSE:ZTS) last released its earnings results on Wednesday, August 3rd. The company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. Zoetis had a net margin of 13.15% and a return on equity of 77.58%. The firm earned $1.20 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the previous year, the business earned $0.43 EPS. The business’s quarterly revenue was up 2.8% compared to the same quarter last year.
A number of other equities research analysts also recently commented on the company. Zacks Investment Research downgraded Zoetis from a “hold” rating to a “sell” rating in a report on Thursday, October 13th. Stifel Nicolaus reaffirmed a “buy” rating and set a $58.00 target price on shares of Zoetis in a research note on Wednesday, October 12th. Bank of America Corp. began coverage on Zoetis in a research note on Thursday, September 29th. They set a “buy” rating and a $60.00 target price for the company. Argus upped their target price on Zoetis from $54.00 to $58.00 and gave the stock a “below average” rating in a research note on Friday, September 9th. Finally, Credit Suisse Group AG reiterated a “focus list” rating and set a $60.00 price target on shares of Zoetis in a research report on Wednesday, September 7th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. Zoetis presently has a consensus rating of “Buy” and an average price target of $55.50.
Zoetis (NYSE:ZTS) traded up 2.06% during mid-day trading on Monday, reaching $51.06. 1,334,951 shares of the company’s stock were exchanged. The stock has a 50-day moving average of $51.23 and a 200-day moving average of $49.13. The firm has a market cap of $25.28 billion, a price-to-earnings ratio of 39.77 and a beta of 1.00. Zoetis has a 12 month low of $38.26 and a 12 month high of $53.14.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Gilder Gagnon Howe & Co. LLC increased its position in Zoetis by 0.4% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 6,730 shares of the company’s stock worth $319,000 after buying an additional 26 shares during the last quarter. Sterneck Capital Management LLC increased its position in Zoetis by 0.7% in the second quarter. Sterneck Capital Management LLC now owns 5,766 shares of the company’s stock worth $274,000 after buying an additional 38 shares during the last quarter. Kistler Tiffany Companies LLC increased its position in Zoetis by 1.1% in the second quarter. Kistler Tiffany Companies LLC now owns 6,231 shares of the company’s stock worth $296,000 after buying an additional 65 shares during the last quarter. Fulton Bank N.A. increased its position in Zoetis by 1.6% in the third quarter. Fulton Bank N.A. now owns 5,279 shares of the company’s stock worth $275,000 after buying an additional 83 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its position in Zoetis by 1.9% in the first quarter. Jones Financial Companies Lllp now owns 6,039 shares of the company’s stock worth $268,000 after buying an additional 114 shares during the last quarter. Institutional investors and hedge funds own 93.14% of the company’s stock.
In other Zoetis news, Director Michael B. Mccallister acquired 2,000 shares of the company’s stock in a transaction dated Tuesday, September 6th. The shares were acquired at an average price of $51.34 per share, for a total transaction of $102,680.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Heidi C. Chen sold 32,097 shares of the stock in a transaction dated Thursday, September 1st. The shares were sold at an average price of $50.98, for a total value of $1,636,305.06. Following the completion of the transaction, the insider now owns 46,060 shares in the company, valued at approximately $2,348,138.80. The disclosure for this sale can be found here. 0.05% of the stock is owned by insiders.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Thursday, November 3rd will be issued a $0.095 dividend. The ex-dividend date of this dividend is Tuesday, November 1st. This represents a $0.38 dividend on an annualized basis and a dividend yield of 0.76%. Zoetis’s payout ratio is currently 29.69%.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.